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562a Tuesday, February 18, 2014myosin subfragment 1 (M2B-S1) was achieved through the generation of re-
combinant adenovirus with subsequent infection in the C2C12 embryonic mus-
cle cell line. A tetracysteine site, which enables site-specific labeling of the
fluorescein biarscenical hairpin-binding dye (FlAsH), was introduced in the up-
per 50 kDa (U50) region (residues 316-321) corresponding to the previously
utilized site in myosin V. Key conformational changes in the myosin motor,
including those associated with nucleotide and actin binding, can be examined
by fluorescence resonance energy transfer (FRET) using M2B-S1 FlAsH and
fluorescent nucleotides or IAEDANs-labeled actin. We demonstrate the enzy-
matic properties of M2B-S1 FlAsH are similar to unlabeled M2B-S1, and both
are capable of moving actin filaments in the in vitromotility assay. We utilized
FRET between M2B-S1 FlAsH and Cy3ATP to examine structural changes in
the U50 domain. The kinetics of structural changes were examined during the
ATP-binding and actin-activated product release steps. We also designed a sys-
tem to study structural changes in the force-generating lever arm using FlAsH
labeling at the N-terminus of a human b-cardiac myosin construct containing a
C-terminal GFP (M2B-GFP). The spectroscopic approach can be used as a tool
to study the effects of hypertrophic cardiomyopathy (HCM) mutations on
myosin structure or to study the impact of drugs that alter myosin motor
activity.
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Embryonic (MYH3), perinatal (MYH8), and alpha (MYH6) myosin heavy
chains are predominantly expressed during prenatal development of human
skeletal and cardiac muscle and may be upregulated following injury. To
determine how mutations in these genes affect performance, development,
and injury recovery, it is important to understand the contractile properties
of the human fetal muscle in which these isoforms are dominant. However,
information on developing human skeletal and cardiac muscle is limited.
We previously reported that human fetal skeletal muscle from a single fetus
of ~16 weeks gestation had slower crossbridge cycling myosin compared to
adult rabbit psoas myosin (in vitro motility measurements) and slower myofi-
bril activation & relaxation kinetics accompanying weaker force production
than adult human skeletal myofibrils (Racca et al. (2013) J.Phys 591:3049-
3061). Here we characterized and compared the contraction and relaxation
properties of human fetal skeletal (HFS) and cardiac (HFC) muscle from
fetuses of ~16 weeks gestation using myofibril mechanics techniques.
HFC muscle was isolated and used fresh, while HFS muscle was flash-
frozen in liquid nitrogen prior to use. The HFC myosin propelled unregulated
F-actin filaments 49% slower than HFS myosin (HFC:1.6650.13mm$s1;
HFS:2.6450.02mm$s1) (2mM ATP, 30C). During maximal calcium
activation (15C), HFC myofibrils produced more force (FMAX=
10.553.6mN/mm2) than HFS (5.951.2mN/mm2), at slightly slower rates
(HFC:kACT=0.4650.09s
1; HFS:0.6650.10s1). The initial (slow) phase of
relaxation was slightly longer in duration (HFC:tREL,slow=203527ms;
HFS:174513ms), and slower in slope (HFC:kREL,slow=0.2650.03s
1;
HFS:0.5950.15s1), indicating slower crossbridge release which may also be
influenced by troponin regulation. The secondary (fast) phase of relaxation
was similar (HFC:kREL,fast=1.850.2s
1;HFS:1.550.2s1). Research to charac-
terize the contractile properties of early development muscle and myosin heavy
chain isoforms is ongoing, and may elucidate their role in development and
muscle repair. Supported by F31AR06300(A.R.), 5K23HD057331(A.B.),
HD048895(M.B.,M.R.).
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Hypertrophic (HCM) and dilated (DCM) cardiomyopathies are important
causes of heart failure, arrhythmia, and sudden cardiac death. HCM is the
most common heritable cardiovascular disorder, affecting 1 in 500 individ-
uals, and is caused primarily by mutations that alter proteins of the cardiac
sarcomere. Sarcomeric protein mutations are an increasingly recognized cause
of familial DCM as well. HCM is associated with severe thickening of the leftventricular wall, preserved/increased systolic (contractile) and impaired dia-
stolic (relaxation) function of the heart. DCM hearts have dilated left ventric-
ular chambers and suffer from inadequate systolic activity. More than 300
point mutations in beta-cardiac myosin are associated with HCM or DCM.
It is believed that HCM and DCM mutations increase and decrease respec-
tively the power output of cardiac myosin which leads to a cascade of down-
stream signaling that gradually leads to the disease phenotype. To test this
hypothesis it is essential to measure the power output of all HCM/DCM mu-
tants in a high throughput manner. To quantitatively measure the load depen-
dent myosin power output, we first improved the loaded in vitro motility assay
(LIMA) by replacing load generating molecule alpha-actinin with alpha-
catenin, which was generously provided by James Nelson at Stanford Univer-
sity. For accurate-and-fast data analysis, we developed a software called
FAST that runs over parallel CPUs. Our initial results indicate that two
HCM mutants (R719W, R403Q) have higher power output than the wildtype
cardiac myosin. FAST-LIMA will be an essential tool for screening drugs that
revert the effects of HCM/DCMmutations on the power output of beta-cardiac
myosin.
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We have identified a small molecule inhibitor, MYK0000461, of the cardiac
myosin ATPase. This agent was characterized in steady state and transient ki-
netic assays to understand its mechanism of action. MYK0000461 decreases
the steady-state rate of the ATPase activity of purified bovine b-cardiac myosin
subfragment-1 (S1) as well as that of bovine cardiac myofibrils, wild type and
the mutant R453C of recombinant human b-cardiac myosin S1. We also find
that MYK0000461 inhibits cardiac myosin selectively as compared to systems
containing rabbit skeletal or chicken smooth muscle myosins Analysis of the
individual steps of the chemo-mechanical cycle of cardiac myosin suggests
that MYK0000461 exerts its effect by inhibiting the actin-stimulated release
of phosphate, presumably by stabilizing the detached state of cardiac myosin
prior to the release of phosphate. We find no evidence to suggest that
MYK000461 inhibits cardiac myosin in a strongly bound state and no other
steps in the chemo-mechanical cycle are affected by MYK0000461. Thus,
the enzymatic step governing the weak to strong transition of S1 binding to
actin is inhibited without affecting the release from the strongly bound states.
This decrease in the rate of transition from the weak to strongly bound state
should decrease force production and may underlie its ability to decrease car-
diac contractility in cellular and in vivo models of cardiac function. An agent
such as MYK0000461 could potentially be used to treat cardiac disorders
that stem from hyper contractility such as the genetic hypertrophic cardiomy-
opathies (HCM). By decreasing the net force of contraction and restoring it
back to normal level could potentially be useful in treating patients that suffer
from this disease.
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The small molecule omecamtiv mecarbil (OM), currently in late phase-2 clin-
ical trials for treatment of heart failure, activates force generation by cardiac
myosin. How OM increases force generation is not known. Crosslinking and
molecular docking studies suggest that the compound binds to the relay/SH1/
converter region of myosin, hypothesized to control the actin-activated pre to
post power-stroke structural transition in the myosin catalytic and light-chain
domains. These transitions drive force production by myosin. We are currently
using time-resolved FRET and EPR distance measurements to detect the pre-
and post-power-stroke structural states of myosin. We have performed these
studies on tissue-purified b-cardiac and a-skeletal myosin, and on a recombi-
nant cys-lite myosin II catalytic domain model from Dictyostelium discoideum.
In each of the myosin isoforms, we find that OM binding increases the mole
fraction of the myosin post power-stroke structural state in the presence of
ATP analogs. Transient time-resolved FRET experiments, mixing FRET-
labeled myosin with ATP, show that drug binding also alters the structural ki-
netics of the myosin recovery-stroke. Ongoing studies are investigating the
